New inhaler drug HRS-9821 enters human safety testing for COPD
NCT ID NCT07116915
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 34 times
Summary
This early-stage study tests whether a new inhaled drug, HRS-9821, is safe and tolerable. It involves 160 participants: healthy volunteers receiving a single dose and COPD patients receiving multiple doses. Researchers will monitor side effects, drug levels in the blood, and heart function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COPD are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital, Sichuan University
RECRUITINGChengdu, Sichuan, 610044, China
Contact
Contact
Conditions
Explore the condition pages connected to this study.